Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line carboplatin + paclitaxel + pembrolizumab with pembrolizumab ± Nesuparib maintenance in pMMR endometrial cancer
KCT0009641Phase 2Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nesuparib in endometrial cancer (EC), sponsored by Onconic Therapeutics Inc.. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
nesuparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0009641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009641.